Salix Pharmaceuticals Ltd (SLXP) Tops Q2 EPS by 6c, Sales Beat Consensus
Tweet
Share
E-mailGet Alerts SLXP Hot Sheet
Join SI Premium – FREE
Salix Pharmaceuticals Ltd (NASDAQ: SLXP) reported Q2 EPS of $0.54, $0.06 better than the analyst estimate of $0.48. Revenue for the quarter came in at $133.2 million versus the consensus estimate of $131.52 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
- KULR Technology Group (KULR) Misses Q2 EPS by 39c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
